Abstracts tagged "systemic lupus erythematosus (SLE) and thrombosis"

Abstract Number: 143 • 2019 ACR/ARP Annual Meeting
Clinical and Genetic Factors Associated with Thrombosis or Pregnancy Morbidity of Antiphospholipid Antibody-Positive Systemic Lupus Erythematosus Patients
Ji-Soong Kim¹, Ga Young Ahn ², Jeongim Choi ³, Jiyoung Lee ⁴, Youngho Park ¹, So-Young Bang ¹ and Sang-Cheol Bae ¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²Guro Hospital, Korea University College of Medicine, Seoul, ³Busan St. Mary's Medical Center, Busan, ⁴Clinical Research Center for Rheumatoid Arthritis, Seoul
Background/Purpose: Antiphospholipid syndrome (APS) is characterized by thromboembolic and obstetric morbidity associated with antiphospholipid antibodies (aPL) in systemic lupus erythematosus (SLE). This study aims to…
Abstract Number: 2893 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes and Response to Anti-Thrombotic Treatment Among Patients with Concomitant Lupus Nephritis and Thrombotic Microangiopathy: A Multicenter Cohort Study
Savino Sciascia¹, Jinoos Yazdany², Maria Jose Cuadrado³, Massimo Radin⁴, Maria Dall'Era², Ishita Aggarwal⁵, Roberta Fenoglio⁶, Antonella Barreca⁷, Mauro Papotti⁷, Irene Cecchi⁸, Elena Rubini⁹, Karen Schreiber¹⁰ and Dario Roccatello⁶, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ²University of California, San Francisco, San Francisco, CA, ³Clinica Universidad de Navarra, Madrid, Spain, ⁴Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Medicine, Santa Clara Valley Medical Center, San Jose, CA, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁷University of Turin, Turin, Italy, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ¹⁰Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom
Background/Purpose: Renal vascular involvement is an important prognostic marker of lupus nephritis (LN). Among patients with various vascular changes, individuals with thromboticmicroangiopathy (TMA) present with…
Abstract Number: 2564 • 2017 ACR/ARHP Annual Meeting
Inhibition of Neutrophil Elastase Protects Against Glomerulonephritis and Thrombosis in a Mouse Model of Lupus
Gautam Sule¹, Levi F. Mazza¹, Nayef M. Kazzaz¹, Srilakshmi Yalavarthi¹, He Meng¹ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²., University of Michigan, Ann Arbor, MI
Background/Purpose: Neutrophils are potential instigators of autoimmunity and effectors of organ damage in lupus. However, there is presently no consensus as to whether inhibition of…
Abstract Number: 17 • 2017 ACR/ARHP Annual Meeting
Thrombotic Events in Pediatric Systemic Lupus Erythematosus: A Preliminary Analysis of a Large, Single-Center Cohort
Jennifer Rammel¹, Martha Curry² and Marietta M. de Guzman³, ¹Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ³Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: While pediatric systemic lupus erythematosus (pSLE) represents only 20% of all SLE cases, pSLE patients often have more aggressive disease with multi-organ involvement. These…
Abstract Number: 664 • 2017 ACR/ARHP Annual Meeting
Low Vitamin D Is Associated with Thrombosis in Systemic Lupus Erythematosus
Michelle Petri¹, Wei Fu² and Daniel Goldman², ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Low vitamin D is common in systemic lupus erythematosus (SLE). It is also found in antiphospholipid syndrome. Vitamin D has effects on tissue factor,…
Abstract Number: 963 • 2016 ACR/ARHP Annual Meeting
Treatment of Homocysteine Improves Urine Protein/Cr Ratio in SLE
Wei Fu¹ and Michelle Petri², ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Homocysteine is a proven prospective risk factor for stroke and arterial thrombosis in SLE. However, checking for homocysteine and treating high levels is actually…
Abstract Number: 1751 • 2016 ACR/ARHP Annual Meeting
Coagulation Pathway Function in Ischemia/Reperfusion Tissue Injury in Autoimmune Prone Mice
Rachel C. Robbins¹, Christopher Tracy², Jess Edison¹, Suzette Peng³ and Chantal Moratz⁴, ¹Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ²Walter Reed National Military Medical Center, Bethesda, MD, ³Food and Drug Administration, Silver Spring, MD, ⁴Uniformed Services University, Bethesda, MD
Results: Tissue Factor Pathway Inhibitor (TFPI) and Anti-thrombin III (ATIII) resulted in reduction of tissue injury, as determined by histopathology scoring. However, TFPI was significantly…
Abstract Number: 2066 • 2016 ACR/ARHP Annual Meeting
Anti-Ds-DNA Antibodies Regulate Atherothrombosis in Systemic Lupus Erythematosus through the Induction of Netosis, the Prothrombotic and Proinflammatory Activities of Monocytes and the Endothelial Activation
Carlos Perez-Sanchez¹, Maria Ángeles Aguirre Zamorano¹, María Galindo², Patricia Ruiz-Limon³, Ivan Arias de la Rosa³, Nuria Barbarroja¹, Yolanda Jiménez-Gómez¹, Pedro Segui¹, Eduardo Collantes-Estévez¹, Maria Jose Cuadrado⁴ and Chary Lopez-Pedrera¹, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ³Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴St Thomas Hospital, Lupus Research Unit, London, United Kingdom
Background/Purpose: The role of anti-dsDNA in the pathogenesis of the systemic lupus erythematosus (SLE) has been clearly established. However, the influence of these autoantibodies in…
Abstract Number: 2992 • 2016 ACR/ARHP Annual Meeting
In Systemic Lupus Erythematosus with Antiphospholipid Antibodies, Hypocomplementemia Associates with Thrombosis
Laura Durcan¹, Wei Fu² and Michelle Petri³, ¹University of Washington, Seattle, WA, ²Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ³Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Hypocomplementemia is a common phenomenon in systemic lupus erythematosus (SLE) and antiphospholipid antibody syndrome (APS). Robust mechanistic data implicate complement activation in antiphospholipid antibody…
Abstract Number: 1832 • 2015 ACR/ARHP Annual Meeting
Recurrence-Rate of Thrombotic Events in SLE Patients Negative for Antiphospholipid Antibodies
Mohammed Attar¹, Jiandong Su², Stacey E. Morrison³, Samar Alharbi⁴, Khawla Al-Ghanim⁵, Dafna Gladman², Murray Urowitz^6,7 and Jorge Sánchez-Guerrero⁸, ¹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Div Rheumatology Rm MP-10-304, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, TWH, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: Thrombotic events (TE) are common in patients with SLE. Antiphospholipid antibodies (aPL) are a risk factor for incident and recurrent TE; therefore these patients…
Abstract Number: 2930 • 2015 ACR/ARHP Annual Meeting
Outcome of Patients with Systemic Lupus Erythematous (SLE) after Thrombotic Events
Samar Alharbi¹, Jiandong Su², Stacey E. Morrison³, Mohammed Attar⁴, Khawla Al-Ghanim⁵, Murray Urowitz^6,7, Dafna Gladman² and Jorge Sánchez-Guerrero⁸, ¹Rheumatology, University Health Network, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Div Rheumatology Rm MP-10-304, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, TWH, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: To assess the impact of thrombotic events (TE) on 1) mortality, 2) SLE-related damage accrual; and 3) health-related quality of life (HRQoL) in patients…
Abstract Number: 2940 • 2015 ACR/ARHP Annual Meeting
Risk Factors for Late-Onset Thrombosis in Systemic Lupus Erythematosus (SLE)
Khawla Al-Ghanim¹, Jiandong Su², Stacey E. Morrison³, Samar Alharbi⁴, Mohammed Attar⁵, Dafna Gladman², Murray Urowitz^6,7 and Jorge Sánchez-Guerrero⁸, ¹Rheumatology, TWH, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Div Rheumatology Rm MP-10-304, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: Thrombotic events (TE) cause great morbidity and mortality in SLE patients. Studies of TE in SLE focus on early-onset TE. While the incidence of…
Abstract Number: 2866 • 2014 ACR/ARHP Annual Meeting
External Validation of the Global Anti-Phospholipid Syndrome Score in Comparison to IgG Antibodies Directed Against Domain I of ß₂-Glycoprotein I. a Prospective Multicentre Cohort Study
Stephane Zuily¹, Bas De Laat², Veronique Regnault³, Pierre Kaminsky⁴, Hilde Kelchtermans⁵, Zakera Shums⁶, Roger Albesa⁷, Gary L Norman⁶, Philip de Groot⁸, Anne-Christine Rat⁹, Jacques Ninet¹⁰, Nadine Magy-Bertrand¹¹, Jean-Louis Pasquali¹², Marc Lambert¹³, Bernard Lorcerie¹⁴, Thomas Lecompte¹⁵, Francis Guillemin¹⁶ and Denis Wahl¹⁷, ¹CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France, ²Biochemistry, CARIM, Maastricht University, Maastricht, Netherlands, ³Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Contrat d’interface, Nancy, F-54000, France, Nancy, France, ⁴Internal Medicine, CHU Nancy, Vandoeuvre, France, ⁵Biochemistry, CARIM, Maastricht University, The Netherlands; Synapse BV, Maastricht, The Netherlands, Maastricht, Netherlands, ⁶INOVA Diagnostics, San Diego, CA, ⁷Research, INOVA Diagnostics, San Diego, CA, ⁸Clinical Chemistry and Hematology, UMC Utrecht, The Netherlands, Utrecht, Netherlands, ⁹University Paris Descartes, EA 4360 APEMAC, University of Lorraine, Nancy, France, ¹⁰Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ¹¹Bensançon University Hospital, Besançon, France, ¹²Service de Medecine Interne, Nouvel Hospital Civil, Strasbourg Cedex, France, ¹³Lille University Hospital, Lille, France, ¹⁴Hopital Du Bocage, Service de Médecine Interne et Immunologie Clinique, Dijon, France, ¹⁵Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Haematology Laboratory, Nancy, F-54000, France; Division of Haematology, HUG, Geneva, Switzerland (current address), Geneva, Switzerland, ¹⁶INSERM, Centre d'Investigation Clinique - Epidémiologie Clinique (CIC-EC) CIE6, Nancy, France, ¹⁷Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy University Hospital and INSERM U961, Vandoeuvre-Les-Nancy, France
Background/Purpose: Our objectives were 1- to perform an external validation of the Global Anti-Phospholipid Syndrome Score (GAPSS) and 2- to compare prognostic significances of GAPPS…
Abstract Number: 2638 • 2014 ACR/ARHP Annual Meeting
The Protective Effects of Statins for Thrombosis in Patients with Systemic Lupus Erythematosus Positive for Antiphospholipid Antibodies
Toshiyuki Watanabe, Kenji Oku, Olga Amengual, Eri Sugawara, Ryo Hisada, Kazumasa Ohmura, Tomoko Fukui, Sanae Shimamura, Ikuma Nakagawa, Atsushi Noguchi, Haruki Shida, Michihito Kono, Yuka Shimizu, Takashi Kurita, Toshiyuki Bohgaki, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Thrombosis is one of the most frequent manifestations in patients with systemic lupus erythematosus (SLE). Although antiphospholipid antibodies (aPL) are well recognized risk factors…
Abstract Number: 2653 • 2013 ACR/ARHP Annual Meeting
Low Vitamin D Is Associated With Increased Risk of Venous Thrombosis in Systemic Lupus Erythematosus, Regardless of Lupus Anticoagulant Status
Michelle Petri and Hong Fang, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Vitamin D deficiency is common in SLE. Vitamin D deficiency is also associated with activation of Tissue Factor. In cross-sectional studies, vitamin D deficiency…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].